|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,146.50 JPY | -1.29% |
|
-1.31% | +2.56% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,896B 24.06B 21.06B 19.41B 17.99B 34.15B 2,284B 34.7B 233B 90.49B 1,127B 90.34B 88.38B | P/E 2027 * |
11.3x | P/E 2028 * | 12x |
|---|---|---|---|---|---|
| Enterprise Value | 3,819B 23.59B 20.64B 19.02B 17.63B 33.47B 2,239B 34.01B 228B 88.71B 1,105B 88.56B 86.64B | EV / Sales 2027 * |
1.7x | EV / Sales 2028 * | 1.69x |
| Free-Float |
97.66% | Yield 2027 * |
3.7% | Yield 2028 * | 3.81% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -1.29% | ||
| 1 week | -1.31% | ||
| Current month | -1.31% | ||
| 1 month | -0.12% | ||
| 3 months | -17.82% | ||
| 6 months | -1.78% | ||
| Current year | +2.56% |
| 1 week | 2,105 |  | 2,216.5 |
| 1 month | 2,041 | | 2,216.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.29% | -1.31% | +55.32% | +4.15% | 24.06B | |
| +2.96% | +3.01% | +59.87% | +173.31% | 1,102B | |
| +3.05% | +5.23% | +72.11% | +67.81% | 643B | |
| -0.04% | +1.20% | +35.72% | +87.93% | 450B | |
| +0.60% | -2.07% | +27.62% | +22.57% | 336B | |
| -1.03% | -0.95% | +28.45% | +47.66% | 288B | |
| -2.92% | +0.95% | -28.01% | -40.86% | 222B | |
| +0.45% | +1.65% | +25.65% | +68.35% | 199B | |
| +5.21% | +7.93% | +21.99% | +83.23% | 169B | |
| +1.48% | -0.04% | -4.64% | -32.25% | 137B | |
| Average | +0.23% | +1.80% | +29.41% | +48.19% | 356.92B | |
| Weighted average by Cap. | +1.30% | +1.84% | +41.80% | +86.78% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.9B 12.16B 11.21B 10.39B 19.72B 1,319B 20.04B 134B 52.27B 651B 52.18B 51.05B | 2,072B 12.8B 11.2B 10.32B 9.57B 18.16B 1,214B 18.45B 124B 48.12B 599B 48.04B 47B |
| Net income | 345B 2.13B 1.86B 1.72B 1.59B 3.02B 202B 3.07B 20.58B 8B 99.7B 7.99B 7.82B | 325B 2.01B 1.76B 1.62B 1.5B 2.85B 190B 2.89B 19.4B 7.54B 93.95B 7.53B 7.37B |
| Net Debt | -76.78B -474M -415M -382M -355M -673M -45.01B -684M -4.59B -1.78B -22.21B -1.78B -1.74B | -391B -2.42B -2.11B -1.95B -1.81B -3.43B -229B -3.48B -23.37B -9.09B -113B -9.07B -8.88B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/07/26 | ¥2,146.50 | -1.29% | 6,198,900 |
| 07/07/26 | ¥2,174.50 | -1.52% | 6,880,100 |
| 06/07/26 | ¥2,208.00 | +2.60% | 4,506,600 |
| 03/07/26 | ¥2,152.00 | +0.58% | 5,173,500 |
| 02/07/26 | ¥2,139.50 | +0.94% | 6,188,700 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
